Virtu KCG Holdings’s Proshares UltraPro NASDAQ Biotechnology UBIO Stock Holding History

Virtu KCG Holdings’s Portfolio UBIO Stock Details UBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-5,573	Closed	-$322K	–	3956
2015 Q4	$322K	Buy	+5,573	New	+$295K	0.01%	2069

Other funds holding UBIO

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Virtu KCG Holdings's UBIO Position: Q1 2016 in Review

Virtu KCG Holdings sold out of Proshares UltraPro NASDAQ Biotechnology (UBIO) in Q1 2016, closing a stake of 5,573 shares — an estimated $322K sold.

Virtu KCG Holdings first reported a position in UBIO in Q4 2015 and held it in 1 quarter. The position peaked at $322K in Q4 2015. 7 funds tracked by Wall St. Rank hold UBIO as of Q1 2016.

Virtu KCG Holdings reported no remaining Proshares UltraPro NASDAQ Biotechnology position as of Q1 2016 after selling out during the quarter.
Virtu KCG Holdings sold 5,573 Proshares UltraPro NASDAQ Biotechnology shares in Q1 2016, an estimated $322K.
Virtu KCG Holdings first reported a position in Proshares UltraPro NASDAQ Biotechnology in Q4 2015 and held it in 1 quarter.
Virtu KCG Holdings's Proshares UltraPro NASDAQ Biotechnology position peaked at $322K in Q4 2015.
7 funds tracked by Wall St. Rank held Proshares UltraPro NASDAQ Biotechnology as of Q1 2016.

Based on Virtu KCG Holdings's 13F filing for Q1 2016, filed 13 May 2016.